Acrivon Therapeutics (ACRV) Non Operating Income (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Non Operating Income of $989000.0 for Q1 2026, down 50.1% year-over-year from $2.0 million in Q1 2025, and down 12.56% quarter-over-quarter from $1.1 million in Q4 2025.
Acrivon Therapeutics (ACRV) Non Operating Income (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Non Operating Income for 6 consecutive years, with $989000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 50.1% year-over-year to $989000.0; the TTM figure through Mar 2026 stood at $5.2 million (down 45.08% YoY), while the FY2025 annual figure was $6.2 million, down 28.16% from the prior year.
- Non Operating Income retreated to $989000.0 in Q1 2026 per ACRV's latest filing, from $1.1 million in the prior quarter.
- Across five years, Non Operating Income topped out at $2.7 million in Q3 2024 and bottomed at -$8000.0 in Q1 2022.
- Historically, Non Operating Income has averaged $1.4 million across 5 years, with a median of $1.6 million in 2023.
- Annual changes were most pronounced in 2023 — Non Operating Income jumped 20562.5% — and 2026, when it plunged 50.1%.
- Acrivon Therapeutics' Non Operating Income stood at $1.0 million in 2022, then surged by 108.96% to $2.1 million in 2023, then changed by 0.0% to $2.1 million in 2024, then tumbled by 46.73% to $1.1 million in 2025, then fell by 12.56% to $989000.0 in 2026.
- Business Quant data shows ACRV's Non Operating Income at $989000.0 in Q1 2026, $1.1 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - | 704,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 860,000.00 |
| Mar 31, 2026 | 989,000.00 |
| Dec 31, 2025 | 1.13 Mn |
| Sep 30, 2025 | 1.45 Mn |
| Jun 30, 2025 | 1.64 Mn |
| Mar 31, 2025 | 1.98 Mn |
| Dec 31, 2024 | 2.12 Mn |
| Sep 30, 2024 | 2.70 Mn |
| Jun 30, 2024 | 2.69 Mn |
| Mar 31, 2024 | 1.18 Mn |
| Dec 31, 2023 | 2.12 Mn |
| Sep 30, 2023 | 1.67 Mn |
| Jun 30, 2023 | 1.61 Mn |
| Mar 31, 2023 | 1.64 Mn |
| Dec 31, 2022 | 1.02 Mn |
| Sep 30, 2022 | 377,000.00 |
| Jun 30, 2022 | 105,000.00 |
| Mar 31, 2022 | -8,000.00 |
| Dec 31, 2021 | -73,000.00 |
| Sep 30, 2021 | 231,000.00 |